Chronic Myelomonocytic Leukemia as Part of a Primary Multiple Malignant Tumor: a Case Report
- 作者: Yashin S.S.1, Kireeva A.O.1
-
隶属关系:
- Samara State Medical University
- 期: 卷 33, 编号 2 (2025)
- 页面: 277-284
- 栏目: Clinical reports
- URL: https://bakhtiniada.ru/pavlovj/article/view/313116
- DOI: https://doi.org/10.17816/PAVLOVJ625773
- EDN: https://elibrary.ru/VOESQE
- ID: 313116
如何引用文章
详细
INTRODUCTION: Chronic myelomonocytic leukemia (CMML) is a rather rare hemoblastosis characterized by damage to the granulocytic and monocytic hematopoietic lineages with the development of relative and absolute monocytosis of the peripheral blood and respective manifestations in the bone marrow. The diagnosis of CMML, like other tumors of hematopoietic, lymphoid and related tissues, is difficult and includes examination of peripheral blood with determination of leukogram parameters, and examination of red bone marrow biopsy specimens. CMML rarely occurs as a part of a primary multiple malignant tumor.
AIM: To demonstrate a rare and difficult to diagnose clinical case of primary multiple tumor: a combination of prostate cancer with renal cell carcinoma and CMML.
In the considered clinical case, the postmortem examination of a patient with a primary multiple malignant tumor with the development of CMML, revealed lesions of lungs, liver, kidneys, spleen, pancreas, retroperitoneal tissue and colon. Based on clinical presentation, the patient was diagnosed with non-specific ulcerative colitis, which on autopsy was interpreted as leukemic lesion of the colon with the development of ulcerative-necrotic colitis. Death resulted from multiorgan failure with phenomena of tumor intoxication.
CONCLUSION: The presented clinical case of CMML demonstrates a polysystemic character of this disease, non-specific symptoms, difficulty in prescribing adequate treatment due to the development of conditions that complicated the main diagnosis, and also shows the probability of developing primary multiple metachronous tumors in patients with various genetic mutations.
作者简介
Sergey Yashin
Samara State Medical University
编辑信件的主要联系方式.
Email: s.s.yashin@samsmu.ru
ORCID iD: 0000-0002-0783-8709
SPIN 代码: 4740-3280
俄罗斯联邦, Samara
Anastasiya Kireeva
Samara State Medical University
Email: nastya2001kireeva@gmail.com
ORCID iD: 0000-0003-3168-3695
SPIN 代码: 8786-4922
俄罗斯联邦, Samara
参考
- Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2017. Vol. 2. P. 82–86.
- Geissler K. Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches. Front Oncol. 2021;11:751668. doi: 10.3389/fonc.2021.751668 EDN: XTRLPW
- Dinmohamed AG, Brink M, Visser O, et al. Trends in Incidence, Primary Treatment and Survival in Chronic Myelomonocytic Leukaemia: a Population-Based Study of 1359 Patients Diagnosed in the Netherlands from 1989 to 2012. Br J Haematol. 2015;171(3):436–439. doi: 10.1111/bjh.13414
- Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703–1719. doi: 10.1038/s41375-022-01613-1 EDN: IOCYIB
- Valent P, Orazi A, Savona MR, et al. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. Haematologica. 2019;104(10):1935–1949. doi: 10.3324/haematol.2019.222059
- Itzykson R, Fenaux P, Bowen D, et al. Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet. Hemasphere. 2018;2(6):e150. doi: 10.1097/hs9.0000000000000150 EDN: FYXXGF
- Kwon J. Diagnosis and Treatment of Chronic Myelomonocytic Leukemia. Blood Res. 2021;56(S1):S5–S16. doi: 10.5045/br.2021.2020321 EDN: UGHLYM
- Gagelmann N, Bogdanov R, Stölzel F, et al. Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. Transplant Cell Ther. 2021;27(1):95.e1–95.e4. doi: 10.1016/j.bbmt.2020.10.007 EDN: IYHHAU
- Pophali P, Matin A, Mangaonkar AA, et al. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. Blood Cancer J. 2020;10(11):121. doi: 10.1038/s41408-020-00387-y EDN: WYTCEO
- Sun Y-Q, Zhao C, Wang Y, et al. Haploidentical stem cell transplantation in patients with chronic myelomonocytic leukemia. Sci China Life Sci. 2020;63(8):1261–1264. doi: 10.1007/s11427-019-1606-3 EDN: ZVGWWN
- Cao Y-G, He Y, Zhang S-D, et al. Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms. Biol Blood Marrow Transplant. 2020;26(2):285–291. doi: 10.1016/j.bbmt.2019.09.001 EDN: PSUYUR
补充文件
